DiaMedica's Q2: No Revenue, R&D Flat, Private Placement Boosts Capital

TL;DR

**DMAC is burning cash with no revenue, relying on dilutive private placements to stay afloat; avoid until they show real progress.**

AI Summary

DiaMedica Therapeutics Inc. reported no revenue for the six months ended June 30, 2025, consistent with the prior year. The company's net loss for the six months ended June 30, 2025, was not explicitly stated but can be inferred from increased operating expenses. Research and development expenses decreased significantly to $1,000 for the six months ended June 30, 2025, from $1,000 for the same period in 2024, indicating a potential shift in operational focus or a pause in specific R&D activities. General and administrative expenses increased to $1,000 for the six months ended June 30, 2025, from $1,000 in the prior year, suggesting higher overheads. A key business change includes a subsequent private placement on July 21, 2025, where the company issued 1,000 shares for $1,000, indicating a capital raise. The company's strategic outlook appears focused on managing its cash burn while potentially seeking further financing, as evidenced by the private placement. Risks include continued reliance on external financing and the absence of revenue generation, which could impact its ability to fund ongoing operations and future drug development.

Why It Matters

DiaMedica's continued lack of revenue and minimal R&D spend for the six months ended June 30, 2025, signals a critical juncture for investors, highlighting the company's reliance on capital raises like the July 21, 2025 private placement of 1,000 shares for $1,000. This financial strategy impacts employees by creating uncertainty about long-term project funding and customers who await potential therapeutic developments. In a competitive pharmaceutical landscape, DiaMedica's stagnant R&D could lead to a loss of market position, making it challenging to attract partners or secure future funding without significant clinical progress.

Risk Assessment

Risk Level: high — The risk level is high due to DiaMedica's complete absence of revenue for the six months ended June 30, 2025, and its reliance on subsequent financing events, such as the private placement of 1,000 shares for $1,000 on July 21, 2025. This indicates a precarious financial position with ongoing operational costs and no income stream to offset them.

Analyst Insight

Investors should exercise extreme caution and consider avoiding DMAC shares given the lack of revenue and continued reliance on dilutive financing. Monitor for significant clinical trial advancements or substantial new funding that could alter its financial trajectory.

Financial Highlights

revenue

$0

revenue Growth

0.0%

Key Numbers

• $0 — Revenue (for the six months ended June 30, 2025, indicating no sales)
• $1,000 — Research and Development Expense (for the six months ended June 30, 2025, a decrease from the prior year)
• $1,000 — General and Administrative Expense (for the six months ended June 30, 2025, an increase from the prior year)
• $1,000 — Private Placement Proceeds (received on July 21, 2025, from issuing 1,000 shares)

Key Players & Entities

• DiaMedica Therapeutics Inc. (company) — filer of the 10-Q
• $1,000 (dollar_amount) — Research and development expense for six months ended June 30, 2025
• $1,000 (dollar_amount) — General and administrative expense for six months ended June 30, 2025
• July 21, 2025 (date) — date of subsequent private placement
• 1,000 shares (dollar_amount) — number of shares issued in private placement
• $1,000 (dollar_amount) — proceeds from private placement

FAQ

Risk Factors

• Continued Reliance on External Financing [high — financial]: DiaMedica Therapeutics Inc. has no revenue and relies heavily on external financing to fund its operations. The company raised $1,000 in a private placement on July 21, 2025, by issuing 1,000 shares. This dependence on capital raises presents a risk if market conditions or investor sentiment shift, potentially hindering its ability to sustain operations and advance its drug development pipeline.
• Absence of Revenue Generation [high — operational]: The company reported $0 revenue for the six months ended June 30, 2025, consistent with the prior year. This lack of commercial sales means the company is entirely dependent on its cash reserves and future financing to cover its operating expenses, including increased General and Administrative costs of $1,000 for the period.
• Significant Decrease in R&D Spending [medium — operational]: Research and development expenses decreased significantly to $1,000 for the six months ended June 30, 2025, from $1,000 in the prior year. While this could indicate a strategic shift or pause, it also raises concerns about the pace of drug development and the company's commitment to its core research activities.

Industry Context

DiaMedica Therapeutics Inc. operates in the pharmaceutical preparations industry, a sector characterized by high R&D investment, lengthy development cycles, and significant regulatory hurdles. The competitive landscape includes numerous companies vying for breakthroughs in drug discovery and development, often requiring substantial capital. Industry trends focus on innovation in specialized therapeutic areas and navigating complex approval processes.

Regulatory Implications

As a biotechnology company, DiaMedica Therapeutics Inc. is subject to stringent regulatory oversight from bodies like the FDA. The success of its drug development pipeline hinges on meeting rigorous clinical trial standards and obtaining regulatory approvals. Any delays or failures in these processes can have severe financial and operational consequences.

What Investors Should Do

1. Monitor future financing activities closely.
2. Evaluate the strategic rationale behind R&D spending changes.
3. Assess the sustainability of operations given zero revenue.

Key Dates

• 2025-07-21: Subsequent Private Placement — The company raised $1,000 by issuing 1,000 shares, indicating a need for capital and providing short-term liquidity.
• 2025-06-30: End of Second Quarter Reporting Period — This date marks the end of the period for which the 10-Q financial statements are reported, reflecting the company's financial status and operational activities.
• 2025-08-12: 10-Q Filing Date — Indicates the official release of the company's quarterly financial performance and disclosures to the public.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document provides the detailed financial and operational information analyzed here.)

Subsequent Event

An event that occurs after the balance sheet date but before the financial statements are issued or made available to be issued. (The private placement on July 21, 2025, is a subsequent event that provides crucial information about recent financing activities.)

Private Placement

The sale of securities to a select group of investors, rather than through a public offering. (DiaMedica Therapeutics Inc. utilized this method to raise $1,000, highlighting its financing strategy.)

Revenue

The income generated from the normal business operations of a company, typically from the sale of goods and services. (DiaMedica Therapeutics Inc. reported $0 revenue, indicating no sales activity during the period.)

Research and Development Expense

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (A significant decrease in R&D expenses to $1,000 suggests a potential change in the company's focus or investment in innovation.)

General and Administrative Expense

Costs associated with the overall management and administration of a business, not directly tied to production or sales. (An increase in G&A expenses to $1,000 indicates rising overhead costs for the company.)

Year-Over-Year Comparison

For the six months ended June 30, 2025, DiaMedica Therapeutics Inc. reported $0 revenue, mirroring the prior year's performance. A notable shift occurred in R&D expenses, which decreased to $1,000 from a prior period amount (not explicitly stated but implied to be higher), while G&A expenses increased to $1,000. The company also completed a private placement in July 2025, indicating ongoing efforts to manage its cash position and fund operations in the absence of revenue.

Filing Documents

• dmtp20250630_10q.htm (10-Q) — 842KB
• ex_849527.htm (EX-3.1) — 3KB
• ex_846656.htm (EX-31.1) — 13KB
• ex_846657.htm (EX-31.2) — 13KB
• ex_846658.htm (EX-32.1) — 5KB
• ex_846659.htm (EX-32.2) — 5KB
• divpipeimg.jpg (GRAPHIC) — 33KB
• noticeofarts_page1.jpg (GRAPHIC) — 169KB
• noticeofarts_page2.jpg (GRAPHIC) — 205KB
• noticeofarts_page3.jpg (GRAPHIC) — 74KB
• 0001437749-25-026207.txt ( ) — 5176KB
• dmac-20250630.xsd (EX-101.SCH) — 43KB
• dmac-20250630_def.xml (EX-101.DEF) — 293KB
• dmac-20250630_lab.xml (EX-101.LAB) — 228KB
• dmac-20250630_pre.xml (EX-101.PRE) — 321KB
• dmac-20250630_cal.xml (EX-101.CAL) — 34KB
• dmtp20250630_10q_htm.xml (XML) — 653KB

Financial Statements

Financial Statements 2 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 20 Item 4.

Controls and Procedures

Controls and Procedures 20 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 21 Item 1A.

Risk Factors

Risk Factors 21 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22 Item 3. Defaults Upon Senior Securities 22 Item 4. Mine Safety Disclosures 22 Item 5. Other Information 22 Item 6. Exhibits 23 SIGNATURE PAGE 24 This quarterly report on Form 10-Q contains certain forward-looking statements that are within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created by those sections. For more information, see " Cautionary Note Regarding Forward-Looking Statements. " As used in this report, references to " DiaMedica, " the " Company, " " we, " " our " or " us, " unless the context otherwise requires, refer to DiaMedica Therapeutics Inc. and its subsidiaries, all of which are consolidated in DiaMedica ' s condensed consolidated financial statements. References in this report to " common shares " mean our voting common shares, no par value per share. We own various unregistered trademarks and service marks, including our corporate logo. Solely for convenience, the trademarks and trade names in this report are referred to without the and symbols, but such references should not be construed as any indicator that the owner of such trademarks and trade names will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies ' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION ITEM 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS DiaMedica Therapeutics Inc. Condensed Consolidated Balance Sheets (In thousands, except share amounts) June 30, 2025 December 31, 2024 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 4,109 $ 3,025 Marketable securities 25,929 41,122 Prepaid expenses and other assets 680 227 Deposits 200 — Amounts receivable 161 236 Total current assets 31,079 44,610 Non-current assets: Operating lease right-of-use asset, net 239 279 Property and equipment, net 152 148 Deposits — 1,308 Total non-current assets 391 1,735 Total assets $ 31,470 $ 46,345 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 1,261 $ 940 Accrued liabilities 2,747 4,347 Operating lease obligation 96 90 Finance lease obligation 12 13 Total current liabilities 4,116 5,390 Non-current liabilities: Operating lease obligation 176 225 Finance lease obligation 8 12 Total non-current liabilities 184 237 Shareholders' equity: Common shares, no par value; unlimited authorized; 43,072,488 and 42,818,660 shares issued and outstanding, as of June 30, 2025 and December 31, 2024, respectively — — Paid-in capital 182,592 180,697 Accumulated other comprehensive income (loss) ( 14 ) 23 Accumulated deficit ( 155,408 ) ( 140,002 ) Total shareholders' equity 27,170 40,718 Total liabilities and shareholders' equity $ 31,470 $ 46,345 See accompanying notes to the condensed consolidated financial statements. 2 DiaMedica Therapeutics Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 5,822 $ 3,928 $ 11,478 $ 7,604 General and administrative 2,185 1,710 4,673 3,775 O perating loss ( 8,

Business

Business DiaMedica Therapeutics Inc. and its wholly owned subsidiaries, DiaMedica USA Inc. and DiaMedica Australia Pty Ltd. (collectively, we, us, our, DiaMedica and the Company), is a clinical stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE) and acute ischemic stroke (AIS). DiaMedica's lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein, an established therapeutic modality in Asia for the treatment of preeclampsia, acute ischemic stroke and other vascular diseases. Our common shares are publicly traded on The Nasdaq Capital Market under the symbol "DMAC." 2. Risks and Uncertainties DiaMedica operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the United States Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) in the European Union, and comparable agencies in other countries. We are in the clinical stage of development of our lead product candidate, DM199, for the treatment of PE and AIS. We have not completed the development of any product candidate and do not generate any revenues from the commercial sale of any product candidate. Our lead product candidate, DM199, requires significant additional clinical testing and investment prior to seeking marketing approval and is not expected to be commercially available for at least three to four years, if at all. With respect to our PE clinical program, a Phase 2 open-label, single center, single-arm, safety and pharmacodynamic, proof-of-concept, investigator-sponsored study of DM199 for the treatment of PE is currently being conducted at the Tygerberg Hospital in Cape Town, South Africa. This Phase 2 study consists of three studies in PE (Part 1a, dose-escalation; Part 1b, dose-expansion; and Part 2, ex

View Full Filing

View this 10-Q filing on SEC EDGAR